Table 2.
Profiles and clinical data for the patients with NBD
| CSF findings at diagnosis | CSF findings after therapy | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| NBD course | Patient no. | Psycosis | Dementia | Neurological symptoms after therapy | BAFF (ng/ml) | Cell counts (/mm3) | IL-6 (pg/ml) | BAFF (ng/ml) | Cell counts (/mm3) | IL-6 (pg/ml) |
| Acute | 1 | − | − | Improved | <0.31 | 160 | 83.6 | <0.31 | 4 | 1.1 |
| Acute | 2 | − | − | Improved | <0.31 | 43 | 0.7 | <0.31 | 5 | 0.9 |
| Acute | 3 | − | − | Improved | <0.31 | 1 | 1.2 | <0.31 | 1 | 0.8 |
| Acute | 4 | − | − | Improved | <0.31 | 53 | 14.6 | <0.31 | 8 | 2.1 |
| Acute | 5 | − | − | Improved | <0.31 | 3 | 0.8 | ND | ND | ND |
| Acute | 6 | − | − | Improved | 6.1 | 57 | 20.3 | ND | ND | ND |
| Acute | 7 | − | − | Improved | 6.3 | 8 | 0.9 | ND | ND | ND |
| Acute | 8 | − | − | Improved | 7.5 | 35 | 0.6 | 8.9 | 4 | 1.1 |
| Acute | 9 | − | − | Improved | 12.4 | 14 | 37.7 | 10.6 | 10 | 3.2 |
| Acute | 10 | − | − | Improved | 5.1 | 12 | 1.1 | ND | ND | ND |
| Chronic | 11 | − | + | Partially improved | 5.4 | 8 | 0.3 | <0.31 | 3 | ND |
| Chronic | 12 | + | − | Partially improved | 5.4 | 37 | 1 | 4.8 | 2 | 0.4 |
| Chronic | 13 | + | − | Partially improved | 10.7 | 6 | 0.9 | 6.2 | 0 | 1.5 |
| Chronic | 14 | + | + | Progressive | 9.3 | 84 | 244.3 | 3.2 | 3 | ND |
| Chronic | 15 | + | − | Died (suicide) | 11.2 | 9 | 0.6 | 8.9 | 5 | 0.9 |
| Chronic | 16 | + | − | Progressive | 10.1 | 3 | 2.1 | 5.6 | 6 | 1 |
| Chronic | 17 | + | + | Progressive | 17.9 | 7 | 1.7 | 11.4 | 12 | 1.8 |
| Chronic | 18 | + | + | Progressive | 11.6 | 2 | 1 | 9.2 | 1 | 1 |
CSF, cerebrospinal fluid; ND, no data; NBD, Neuro-Behçet's disease.